In the journey to outperform the market, investors delve into the art of stock selection. Choosing the right stocks can be a powerful driver for wealth accumulation.
As of close of business last night, Ironwood Pharmaceuticals Inc’s stock clocked out at $0.93, up 2.24% from its previous closing price of $0.91. In other words, the price has increased by $2.24 from its previous closing price. On the day, 1.98 million shares were traded. IRWD stock price reached its highest trading level at $0.9785 during the session, while it also had its lowest trading level at $0.9.
Ratios:
To gain a deeper understanding of IRWD’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 1.70 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 1.46. For the most recent quarter (mrq), Quick Ratio is recorded 4.69 and its Current Ratio is at 4.69.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Feb 10 ’25 when MCCOURT Thomas A sold 139,064 shares for $1.76 per share. The transaction valued at 244,753 led to the insider holds 1,160,634 shares of the business.
Silver Ronald sold 12,048 shares of IRWD for $21,204 on Feb 10 ’25. The Principal Accounting Officer now owns 279,655 shares after completing the transaction at $1.76 per share. On Feb 10 ’25, another insider, Shetzline Michael, who serves as the SVP, CMO, Head-Res&Drug of the company, sold 41,269 shares for $1.76 each. As a result, the insider received 72,633 and left with 554,007 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 150864784 and an Enterprise Value of 661776960. As of this moment, Ironwood’s Price-to-Earnings (P/E) ratio for their current fiscal year is 86.32, and their Forward P/E ratio for the next fiscal year is 2.48. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.61. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.43. Its current Enterprise Value per Revenue stands at 1.883 whereas that against EBITDA is 6.772.
Stock Price History:
The Beta on a monthly basis for IRWD is 0.37, which has changed by -0.88532674 over the last 52 weeks, in comparison to a change of 0.09765589 over the same period for the S&P500. Over the past 52 weeks, IRWD has reached a high of $8.45, while it has fallen to a 52-week low of $0.59. The 50-Day Moving Average of the stock is -27.12%, while the 200-Day Moving Average is calculated to be -73.27%.
Shares Statistics:
It appears that IRWD traded 3.85M shares on average per day over the past three months and 2446440 shares per day over the past ten days. A total of 160.21M shares are outstanding, with a floating share count of 156.66M. Insiders hold about 3.18% of the company’s shares, while institutions hold 85.63% stake in the company. Shares short for IRWD as of 1744675200 were 11642399 with a Short Ratio of 3.03, compared to 1741910400 on 16247025. Therefore, it implies a Short% of Shares Outstanding of 11642399 and a Short% of Float of 10.93.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
A detailed examination of Ironwood Pharmaceuticals Inc (IRWD) is currently in progress, with 1.0 analysts providing valuable insights into its market dynamics.The consensus estimate for the next quarter is $0.04, with high estimates of $0.04 and low estimates of $0.03.
Analysts are recommending an EPS of between $0.22 and $0.18 for the fiscal current year, implying an average EPS of $0.21. EPS for the following year is $0.44, with 4.0 analysts recommending between $1.12 and $0.01.
Revenue Estimates
In the current quarter, 3 analysts expect revenue to total $59.93M. It ranges from a high estimate of $79.9M to a low estimate of $43.9M. As of the current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $74.88MFor the next quarter, 3 analysts are estimating revenue of $69.43M. There is a high estimate of $99.9M for the next quarter, whereas the lowest estimate is $54.8M.
A total of 6 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $376M, while the lowest revenue estimate was $264M, resulting in an average revenue estimate of $286.75M. In the same quarter a year ago, actual revenue was $351.41MBased on 5 analysts’ estimates, the company’s revenue will be $308.68M in the next fiscal year. The high estimate is $534M and the low estimate is $226M.
